Page 1

25/08/2026 , 09:52 Bausch + Lomb News Releases Bausch + Lomb Advancing Two First - in - Class Eye Health Therapies Based on Trial Results AUGUST 24 , 2026 Dual - action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $ 2 billion assuming successful development and commercialization¹ VAUGHAN , Ontario -- ( BUSINESS WIRE ) -- Bausch + Lomb Corporation ( NYSE / TSX : BLCO ) , a leading global eye health company dedicated to helping people see better to live better , today announced that two of its pharmaceutical pipeline assets - both first - in - class treatments - will advance to new trials based on recent clinical results . " Helping people see better to live better starts with tackling the challenges patients still face every day , " said Bausch + Lomb CEO Brent Saunders . “ These results support our approach to developing differentiated therapies that have the potential to address significant unmet needs and change the standard of care in eye health . " Dry Eye Disease Dual - Action Eye Drop : Phase 2 Results Support Advancement to Phase 3 with Day 15 Primary Endpoint Dry eye disease is a complex , multifactorial condition affecting millions of people worldwide . While existing prescription therapies can effectively address individual causes of dry eye disease , no approved treatment addresses both the inflammatory and evaporative drivers of the disease in a single therapy . Patients often continue to experience persistent symptoms despite treatment , highlighting the need for new approaches that more comprehensively address the condition . Bausch + Lomb has developed a first - in - class dual - action eye drop that combines 5 % lifitegrast ( the active ingredient in XIIDRAⓇ ) and perfluorohexyloctane ( PFHO ; the active ingredient in MIEBOⓇ ) into a single twice - daily treatment designed to address both ocular surface inflammation and tear evaporation – two of the primary underlying causes of dry eye disease . Study Design and Results A four - week , randomized , double - masked , parallel - group , active - controlled Phase 2 study enrolled 443 patients with dry eye disease ( age 18 and older ) across six arms : the dual - action eye drop , lifitegrast alone , PFHO alone and three vehicle masking controls . This was the first clinical study of the combination , and Day 29 was selected as the primary endpoint timepoint in the absence of prior human data on the timing of the combined treatment effect . https://www.bausch.com/newsroom/news/?id=361 1/5 15